scispace - formally typeset
M

Mercedes Yritia

Researcher at Autonomous University of Barcelona

Publications -  8
Citations -  402

Mercedes Yritia is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Tetrahydroharmine & N,N-Dimethyltryptamine. The author has an hindex of 4, co-authored 8 publications receiving 339 citations.

Papers
More filters
Journal ArticleDOI

Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics

Jordi Riba, +5 more
- 01 Jul 2003 - 
TL;DR: Drug administration increased urinary normetanephrine excretion, but, contrary to the typical MAO-inhibitor effect profile, deaminated monoamine metabolite levels were not decreased, suggesting a predominantly peripheral (gastrointestinal and liver) site of action for harmine.
Journal ArticleDOI

Determination of N,N-dimethyltryptamine and β-carboline alkaloids in human plasma following oral administration of Ayahuasca

Mercedes Yritia, +7 more
- 05 Nov 2002 - 
TL;DR: The gas chromatography and HPLC methods described allowed adequate characterization of the pharmacokinetics of the four main alkaloids present in ayahuasca, and also of two major beta-carboline metabolites not previously described in the literature.
Journal Article

Determination of N, N-dimethyltryptamine and β-carboline alkaloids in human plasma following oral administration of Ayahuasca

Mercedes Yritia, +7 more
- 01 Jan 2002 - 
TL;DR: In this paper, an analytical methodology for the plasma quantification of the four main alkaloids present in ayahuasca plus two major metabolites is described, and the results showed good recoveries, above 87%, and accuracy and precision better than 13.4%.
Journal ArticleDOI

Treatment simplification to once daily darunavir/ ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients:

José Moltó, +10 more
- 01 Feb 2010 - 
TL;DR: Treatment simplification to darunavir/-ritonavir 900/100 mg once daily guided by the dar unavir virtual inhibitory quotient (vIQ) in treatment-experienced HIV-infected patients receiving salvage therapy seems to be safe enough to be tested in adequately powered clinical trials.
Journal ArticleDOI

Bioequivalence study of two different film-coated tablet formulations of losartan-hydrochlorothiazide in healthy volunteers.

Rita Neves, +6 more
- 15 Dec 2011 - 
TL;DR: It can be concluded that the evaluated formulations are bioequivalence in terms of rate and extent of absorption.